CMPI to Host Hill Briefing on Follow-On Biologic Drugs for Media and Congressional Staff with Reps. Eshoo and Rogers
Representative Eshoo’s legislation: H.R. 1548, the Pathway for Biosimilars Act ensures that new standards for testing will make certain that follow-on biologic drugs are both safe and effective. The bill currently has 108 cosponsors and has the broadest bipartisan support of any legislation designed to regulate follow-on biologics.
“CMPI applauds Representatives Eshoo’s and Rogers’ commitment to ensuring patient safety is the top-priority for follow-on biologics legislation,” said
Also speaking at the event will be former Congressman
WHAT: Briefing for media and Congressional staff
WHERE: Cannon Caucus Room, Cannon House Office Building 3rd Floor,
WHY: A Follow-On Biologics Legislation Update; Congressional Leaders and Medical Experts Discuss Patient Safety
Those interested in attending this event can RSVP via email to
The Center for Medicine in the Public Interest, a non-profit public policy group dedicated to research-based free market reforms for the health care industry.
SOURCE Center for Medicine in the Public Interest